Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a strong investment opportunity by hedge funds, with multiple analysts providing updated price targets and ratings [1][3][4] Group 1: Analyst Ratings and Price Targets - RBC Capital maintained a Hold rating on Regeneron, setting a price target of $745.00 on February 10 [1] - Guggenheim raised its price target for Regeneron to $975 from $865 on February 9, maintaining a Buy rating, citing key upcoming catalysts [3] - Oppenheimer increased its price target to $865 from $750 while keeping an Outperform rating, noting that Regeneron's fiscal Q4 earnings were largely in line with consensus estimates [4] Group 2: Company Overview and Developments - Regeneron Pharmaceuticals focuses on developing therapies for various diseases, including cancer, eye disorders, and allergic conditions [5] - Key upcoming catalysts for Regeneron include data on fianlimab/Libtayo for melanoma, an FDA decision for the Eylea HD pre-filled syringe in Q2, and an NDA submission for cemdisiran in generalized myasthenia gravis in Q1 [3]